Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.

Citation metadata

Date: Feb. 8, 2019
From: Journal of Hematology & Oncology(Vol. 12, Issue 1)
Publisher: BioMed Central Ltd.
Document Type: Report
Length: 9,124 words
Lexile Measure: 1240L

Document controls

Main content

Abstract :

The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is being made. In addition to the tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive ALL, immunotherapeutic agents, blinatumomab, inotuzumab ozogamicin (INO), and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Blinatumomab and INO are being incorporated into induction chemotherapy regimens and combined with TKIs for ALL therapy. A novel low-intensity regimen, miniHCVD-INO-blinatumomab, appears to be less toxic and more effective than conventional intensive chemotherapy regimens. This review summarized new therapeutic researches of ALL and updated latest progress in clinical trials on bispecific antibodies, antibody-drug conjugates, and new regimens incorporating these novel antibodies. Keywords: Acute lymphoblastic leukemia, Bispecific antibody, Antibody-drug conjugate, Chimeric antigen receptor, Hyper-CVAD

Source Citation

Source Citation   

Gale Document Number: GALE|A581360993